Racial/Ethnic Disparities in Mental Health Care: Real-World Strategies to Address Inequities in Treatment and Outcomes

Faculty

Monica E. Peek, MD, MPH, MSc
(she/her/hers)
Ellen H. Block Professor of Health Justice in the Department of Medicine
Associate Director, Chicago Center for Diabetes Translation Research
Director of Research, MacLean Center for Clinical Medical Ethics
The University of Chicago
Chicago, IL
Monica E. Peek, MD, MPH, MSc

Monica Peek, MD, MPH, MSc is an Ellen H. Block Professor of Health Justice in the Department of Medicine. She is also the Associate Director, Chicago Center for Diabetes Translation Research, and Director of Research, MacLean Center for Clinical Medical Ethics. She is a practicing internist, medical educator, and clinician investigator. Her research pursues health equity and social justice, with a focus on promoting equitable doctor/patient relationships among racial minorities, integrating the medical and social needs of patients, and addressing health care discrimination and structural racism impacting health outcomes (e.g., diabetes, COVID-19). Dr. Peek has authored more than 200 peer-reviewed publications and abstracts on health care disparities, diversity, and bias; has been the principal investigator of multiple grants to address health disparities; and has been invited to speak at numerous local and national medical meetings.

Rakesh Jain, MD, MPH
Clinical Professor, Department of Psychiatry
Texas Tech Health Sciences Center School of Medicine – Permian Basin
Midland, TX
Rakesh Jain, MD, MPH

Rakesh Jain, MD, MPH, is a Clinical Professor in the department of Psychiatry at the Texas Tech Health Sciences Center School of Medicine – Permian Basin in Midland, Texas and in private practice in Austin, Texas. Dr. Jain attended medical school at the University of Calcutta in India. He received his Master of Public Health (MPH) degree from the University of Texas School of Public Health in Houston, where he was awarded a National Institute/Center for Disease Control Competitive Traineeship. His research thesis focused on the impact of substance abuse.

Dr. Jain completed his residency in psychiatry at the Department of Psychiatry and Behavioral Sciences at the University of Texas Medical School at Houston. He then completed a postdoctoral fellowship in research psychiatry at the University of Texas Mental Sciences Institute in Houston. He was awarded the National Research Service Award in support of his postdoctoral fellowship.

Dr. Jain has been involved in over 100 research projects studying the effects of medications on short-term and long-term treatment of depression, anxiety, pain/mood overlap disorders, ADHD, and psychosis in adult and child/adolescent populations. He has presented at the World Psychiatric Congress held in Prague, and at Depression and Pain Forum meetings internationally. He is the author of 55 articles published in various journals and magazines, such as the Journal of Psychiatric Research and  Journal of Clinical Psychiatry, among others, and has presented over 25 original research posters at meetings such as the American Psychological Association (APA), the American College of Neuropsychopharmacology (ACNP), the American Academy of Child and Adolescent Psychiatry (AACAP), the U.S. Psychiatric Congress, and more. He has co-authored six books that range from patient education to cutting-edge neurobiologic findings in psychiatry and mental health. He serves on several advisory boards focusing on drug development and disease state education. He was also recently the Chair of the U.S. Psychiatric Congress, and for several years, has served as a member of the Steering Committee for U.S. Psychiatric Annual Congress. He is a recipient of the Public Citizen of the Year award from the National Association of Social Workers, Gulf Coast Chapter, in recognition of his community and peer education, and championing of mental health issues.

Statement of Need

Though the overall prevalence of major depressive disorder (MDD) is estimated to be largely equivalent across racial/ethnic groups, there is a significant disparity in the rate of diagnosis of MDD for many racial/ethnic underserved communities, including Black and Hispanic groups. In addition, amongst those from these communities who do receive a diagnosis, treatment offerings are often limited, with antidepressant therapy as well as psychotherapy offered at lower rates as compared to their non-Hispanic White counterparts. Social determinants / drivers of health play an additional role in these disparate outcomes, as negative drivers of health have been associated with progression to treatment resistant depression (TRD). It is imperative that each member of the multidisciplinary care team works together to address these disparities in order to improve equity in treatment and outcomes for all patients.

In this CMEO BriefCase, expert faculty will utilize case-based learning to illustrate these pervasive disparities through the stories of two patients, Luna and Eralia, while offering strategies to address inequities in the treatment and outcomes of patients with MDD and/or TRD.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Implement strategies to address inequities in the treatment and outcomes of patients with major depressive disorder
  • Implement strategies to address inequities in the treatment and outcomes of patients with treatment resistant depression

Financial Support

Supported by an educational grant provided by Johnson & Johnson.

Target Audience

Physicians specializing in psychiatry, primary care, or emergency medicine, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, psychologists, counselors, social workers, and case managers

Credit Information

Jointly accredited provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Interprofessional (IPCE) 1.0

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.00 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Pharmacists (ACPE) 1.0

This application-based activity is approved for 1.00 contact hours ( 0.1 CEUs) of continuing pharmacy credit ( JA0007185-0000-23-145-H01-P ).

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until 12/19/2026. PAs should only claim credit commensurate with the extent of their participation.

Social Work (ACE) 1.0

As a Jointly Accredited Organization, CME Outfitters, LLC is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. CME Outfitters, LLC maintains responsibility for this course. Social workers completing this course receive 1.00 intermediate continuing education credits.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Dr. Peek reports no financial relationships to disclose.

Dr. Jain reports the following financial relationships:

Advisory Board: Adamas Pharmaceuticals, Inc.; Alkermes; Corium, Inc.; Eisai Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Sage Therapeutics, Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Usona Institute

Consultant: AbbVie Inc. (Allergan); Acadia Pharmaceuticals Inc.; Adamas Pharmaceuticals, Inc.; Alfasigma USA, Inc.; Axsome Therapeutics, Inc.; Biogen; Boehringer Ingleheim; Corium, Inc.; Cingulate; Eisai Inc.; Evidera; Impel Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Osmotica Pharmaceuticals; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Sage Therapeutics, Inc; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Teva Pharmaceuticals USA, Inc.; and Transcend Therapeutics

Research Support: AbbVie Inc. (Allergan); Lilly; Lundbeck; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Shire Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.

Speakers Bureau: AbbVie Inc. (Allergan); Alkermes; Axsome Therapeutics, Inc.; Corium, Inc.; Eisai Inc.; Indivior; Intra-Cellular Therapies, Inc.; Ironshore Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Lundbeck; Merck & Co., Inc.; Neos Therapeutics, Inc.; Neurocrine Biosciences, Inc.; Otsuka America Pharmaceutical, Inc.; Pamlab; Pfizer Inc.; Shire Pharmaceuticals; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A., Inc.; and Tris Pharma, Inc.

 

The following individuals have no financial relationships to disclose: 

Marlon (Tony) Graham, MD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Morgan Stockberger, MD (Planning Committee)
Jessica Whelan, DNP, APRN, FPMHNP-BC, RN-BC (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

BC-109-121923-57

Racial/Ethnic Disparities in Mental Health Care: Real-World Strategies to Address Inequities in Treatment and Outcomes
Event Date: 12/19/2023 at 5:00 am EST